KRAS and malignant colon neoplasm: Although combinations of CHEK1i with DNA-damaging agents have been linked to TP53- and KRAS-mutant cancer24,25, to our knowledge, this is the first report of notable activity in MSS and KRAS–TP53 double-mutant colon cancer.